

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (original): A method of ameliorating the symptoms of postpartum psychosis in a patient in need thereof, comprising administering an amount of a glucocorticoid receptor antagonist effective to ameliorate the symptoms of the postpartum psychosis, with the proviso that the first psychotic symptoms arise within nine months of childbirth, that the patient has never suffered any psychotic condition not triggered by childbirth, and that the patient did not suffer from psychosis prior to parturition.

2. (original): The method of claim 1, wherein the first psychotic symptoms arise within eight weeks of childbirth.

3. (original): The method of claim 1, wherein the glucocorticoid receptor antagonist comprises a steroidal skeleton with at least one phenyl-containing moiety in the 11- $\beta$  position of the steroidal skeleton.

4. (original): The method of claim 3, wherein the phenyl-containing moiety in the 11- $\beta$  position of the steroidal skeleton is a dimethylaminophenyl moiety.

5. (original): The method of claim 4, wherein the glucocorticoid receptor antagonist comprises mifepristone.

6. (original): The method of claim 4, wherein the glucocorticoid receptor antagonist is selected from the group consisting of 11 $\beta$ -(4-dimethylaminoethoxyphenyl)-17 $\alpha$ -propynyl-17 $\beta$ -hydroxy-4,9 estradien-3-one and 17 $\beta$ -hydroxy-17 $\alpha$ -19-(4-methylphenyl)androsta-4,9(11)-dien-3-one.

7. (original): The method of claim 1 wherein the glucocorticoid receptor antagonist is selected from the group consisting 4 $\alpha$ (S)-Benzyl-2(R)-prop-1-ynyl-1,2,3,4,4 $\alpha$ ,9,10,10 $\alpha$ (R)-octahydro-phenanthrene-2,7-diol and 4 $\alpha$ (S)-Benzyl-2(R)-chloroethynyl-1,2,3,4,4 $\alpha$ ,9,10,10 $\alpha$ (R)-octahydro-phenanthrene-2,7-diol.

8. (original): The method of claim 1, wherein the glucocorticoid receptor antagonist is (11 $\beta$ ,17 $\beta$ )-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one.

9. (original): The method of claim 1, wherein the administration is once per day.

10. (original): The method of claim 1, wherein the mode of administration is oral.

11. (original): The method of claim 1, wherein the mode of administration is by a transdermal application, by a nebulized suspension, or by an aerosol spray.

Claims 12-14 (canceled)

15. (new): The method of claim 1, wherein the glucocorticoid receptor antagonist is a specific glucocorticoid receptor antagonist.